POLBF (Poolbeg Pharma) ROCE % : -37.73% (As of Jun. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Poolbeg Pharma ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Poolbeg Pharma's annualized ROCE % for the quarter that ended in Jun. 2024 was -37.73%.

Poolbeg Pharma ROCE % Historical Data

The historical data trend for Poolbeg Pharma's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Poolbeg Pharma ROCE % Chart

Poolbeg Pharma Annual Data

Trend

Dec21

Dec22

Dec23

ROCE %

-10.34

-23.20

-29.22

Poolbeg Pharma Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
ROCE %	Get a 7-Day Free Trial			-15.38	-32.55	-24.34	-33.63	-37.73

Poolbeg Pharma ROCE % Calculation

Poolbeg Pharma's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-5.932	/	( ( (23.495 - 1.177)	+	(19.529 - 1.248) )	/ 2 )
	=	-5.932	/	( (22.318	+	18.281)	/ 2 )
	=	-5.932	/	20.2995
	=	-29.22 %

Poolbeg Pharma's ROCE % of for the quarter that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Jun. 2024 )		(Q: Dec. 2023 )		(Q: Jun. 2024 )
	=	-6.436	/	( ( (19.529 - 1.248)	+	(16.552 - 0.714) )	/ 2 )
	=	-6.436	/	( ( 18.281	+	15.838 )	/ 2 )
	=	-6.436	/	17.0595
	=	-37.73 %

(1) Note: The EBIT data used here is two times the semi-annual (Jun. 2024) EBIT data.

Poolbeg Pharma (OTCPK:POLBF) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Poolbeg Pharma ROCE % Related Terms

Thank you for viewing the detailed overview of Poolbeg Pharma's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Poolbeg Pharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poolbeg Pharma PLC (OTCPK:POLBF) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

POLB:UK 7JN:Germany

Address

42 New Road, Queen Mary BioEnterprises Innovation Centre, London, GBR, E1 2AX

Website

https://www.poolbegpharma.com

Poolbeg Pharma PLC is a clinical-stage infectious disease pharmaceutical company, with a novel capital-light clinical model which enables to develop of multiple products faster and more cost-effectively than the traditional biotech model. The company aspires to become a one-stop shop for pharma-seeking mid-stage products to license or acquire.